Automated Insulin Delivery Systems in Cystic Fibrosis-Related Diabetes: A Systematic Review and Meta-Analysis
Authors' conclusion
AIDs improved glycemic control in pwCFRD without increasing hypoglycemia, with short-term benefits persisting over 12 weeks.
Study context
- Population
- People with cystic fibrosis-related diabetes; studies with ≥14 days follow-up reporting CGM outcomes
- Participants
- 69 people4 studies
- Comparison
- AID systems
- Outcome
- TIR (3.9-10.0 mmol/L or 70-180 mg/dL)
Methodological detailssingle-arm meta-analyses, random-effects model, Searched MEDLINE (via PubMed), Embase and Cochrane Library
- Single-arm meta-analyses
- Random-effects model
- Searched MEDLINE (via PubMed), Embase and Cochrane Library
Pooled result
As reported in the abstract
TIR
Estimate (95% CI)P value
AIDs
increase in TIR, short-term (14-30 days) 9.55 %(1.49–17.61)
P = 0.02AIDs
increase in TIR, long-term (≥12 weeks) 11.55 %(5.61–17.50)
P < 0.001Further pooled results
TAR (>10.0 mmol/L or 180 mg/dL) · short-term (14-30 days) and long-term (≥12 weeks)
- TAR decrease, short-term
- 8.41% (95% CI −15.59, −1.22; P = .022)
- TAR decrease, long-term
- 12.96% (95% CI −17.67, −8.26; P < .001)
- Single-arm meta-analysis, random-effects model
Average glucose · short-term (14-30 days) and long-term (≥12 weeks)
- Average glucose decrease, short-term
- 1.01 mmol/L (18 mg/dL) (95% CI −1.98, −0.04; P = .042)
- Average glucose decrease, long-term
- 1.12 mmol/L (20 mg/dL) (95% CI −1.70, −0.54; P < .001)
- Single-arm meta-analysis, random-effects model
TBR, BMI and FEV1
- Automated insulin delivery systems (AIDs) did not change TBR, BMI and FEV1
Safety
TBR (<3.9 mmol/L or 70 mg/dL)
- AIDs did not change TBR
Original publication
Automated Insulin Delivery Systems in Cystic Fibrosis-Related Diabetes: A Systematic Review and Meta-Analysis. Endocr Pract. Published 1 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →